This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jin, X. Articles by Markowitz, M. Search for Related Content PubMed PubMed Citation Articles by Jin, X. Articles by Markowitz, M.

 Previous Article  |  Next Article 

Journal of Virology, March 2002, p. 2206-2216, Vol. 76, No. 5
0022-538X/02/$04.00+0     DOI: 10.1128/jvi.76.5.2206-2216.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeficiency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral Therapy^,

Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016,¹ Aventis Pasteur,² EFS Rhone Alpes, Lyon, France,³ IDM Biotech, Montreal, Quebec, Canada H3T 1C3⁴

Received 7 August 2001/ Accepted 26 November 2001

In order to boost immune responses in persons in whom highly active antiretroviral therapy (HAART) was initiated within 120 days of the onset of symptoms of newly acquired human immunodeficiency virus type 1 (HIV-1) infection, we administered vaccines containing a canarypox virus vector, vCP1452, with HIV-1 genes encoding multiple HIV-1 proteins, and recombinant gp160. Fifteen HIV-1-infected subjects who achieved sustained suppression of plasma viremia for at least 2 years were enrolled. While continuing antiretroviral therapy, each subject received at least four intramuscular injections of the vaccines on days 0, 30, 90, and 180. Adverse events were mild, with the most common being transient tenderness at the vCP1452 injection site. Of the 14 patients who completed vaccination, 13 had significant increases in anti-gp120 or anti-p24 antibody titers, and 9 had transient augmentation of their T-cell proliferation responses to gp160 and/or p24. HIV-1-specific CD8⁺ T cells were quantified using an intracellular gamma interferon staining assay. Among 11 patients who had increased CD8⁺ T-cell responses, seven had responses to more than one HIV-1 antigen. In summary, vaccination with vCP1452 and recombinant gp160 appears safe and immunogenic in newly HIV-1-infected patients on HAART.

Present address: University of Rochester Medical Center, Rochester, NY 14642.

Present address: The Scripps Research Institute, La Jolla, CA 92037.

This article has been cited by other articles:

• Wilson, C. C., Newman, M. J., Livingston, B. D., MaWhinney, S., Forster, J. E., Scott, J., Schooley, R. T., Benson, C. A. (2008). Clinical Phase 1 Testing of the Safety and Immunogenicity of an Epitope-Based DNA Vaccine in Human Immunodeficiency Virus Type 1-Infected Subjects Receiving Highly Active Antiretroviral Therapy. CVI 15: 986-994 [Abstract] [Full Text]  
• Hanke, T., McMichael, A. J., Dorrell, L. (2007). Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J. Gen. Virol. 88: 1-12 [Abstract] [Full Text]  
• Dorrell, L., Yang, H., Ondondo, B., Dong, T., di Gleria, K., Suttill, A., Conlon, C., Brown, D., Williams, P., Bowness, P., Goonetilleke, N., Rostron, T., Rowland-Jones, S., Hanke, T., McMichael, A. (2006). Expansion and Diversification of Virus-Specific T Cells following Immunization of Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals with a Recombinant Modified Vaccinia Virus Ankara/HIV-1 Gag Vaccine.. J. Virol. 80: 4705-4716 [Abstract] [Full Text]  
• Pal, R., Venzon, D., Santra, S., Kalyanaraman, V. S., Montefiori, D. C., Hocker, L., Hudacik, L., Rose, N., Nacsa, J., Edghill-Smith, Y., Moniuszko, M., Hel, Z., Belyakov, I. M., Berzofsky, J. A., Parks, R. W., Markham, P. D., Letvin, N. L., Tartaglia, J., Franchini, G. (2006). Systemic Immunization with an ALVAC-HIV-1/Protein Boost Vaccine Strategy Protects Rhesus Macaques from CD4+ T-Cell Loss and Reduces both Systemic and Mucosal Simian-Human Immunodeficiency Virus SHIVKU2 RNA Levels.. J. Virol. 80: 3732-3742 [Abstract] [Full Text]  
• Trkola, A., Kuster, H., Leemann, C., Oxenius, A., Fagard, C., Furrer, H., Battegay, M., Vernazza, P., Bernasconi, E., Weber, R., Hirschel, B., Bonhoeffer, S., Gunthard, H. F. (2004). Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point. Blood 104: 1784-1792 [Abstract] [Full Text]  
• Autran, B., Carcelain, G., Combadiere, B., Debre, P. (2004). Therapeutic Vaccines for Chronic Infections. Science 305: 205-208 [Abstract] [Full Text]  
• Kinloch-de Loes, S. (2004). Role of therapeutic vaccines in the control of HIV-1. J Antimicrob Chemother 53: 562-566 [Abstract] [Full Text]  
• Tulman, E. R., Afonso, C. L., Lu, Z., Zsak, L., Kutish, G. F., Rock, D. L. (2004). The Genome of Canarypox Virus. J. Virol. 78: 353-366 [Abstract] [Full Text]  
• Santini, S. M., Belardelli, F. (2003). Advances in the Use of Dendritic Cells and New Adjuvants for the Development of Therapeutic Vaccines. Stem Cells 21: 495-505 [Abstract] [Full Text]  
• Jin, X., Gao, X., Ramanathan, M. Jr., Deschenes, G. R., Nelson, G. W., O'Brien, S. J., Goedert, J. J., Ho, D. D., O'Brien, T. R., Carrington, M. (2002). Human Immunodeficiency Virus Type 1 (HIV-1)-Specific CD8+-T-Cell Responses for Groups of HIV-1-Infected Individuals with Different HLA-B*35 Genotypes. J. Virol. 76: 12603-12610 [Abstract] [Full Text]  
• Tryniszewska, E., Nacsa, J., Lewis, M. G., Silvera, P., Montefiori, D., Venzon, D., Hel, Z., Parks, R. W., Moniuszko, M., Tartaglia, J., Smith, K. A., Franchini, G. (2002). Vaccination of Macaques with Long-Standing SIVmac251 Infection Lowers the Viral Set Point After Cessation of Antiretroviral Therapy. J. Immunol. 169: 5347-5357 [Abstract] [Full Text]